To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Aspects on radionuclide t… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Aspects on radionuclide therapy in malignant pheochromocytomas.

Journal article
Authors Eva Forssell-Aronsson
Peter Bernhardt
Bo Wängberg
Lars Kölby
Ola Nilsson
Håkan Ahlman
Published in Annals of the New York Academy of Sciences
Volume 1073
Pages 498-504
ISSN 0077-8923
Publication year 2006
Published at Institute of Clinical Sciences, Department of Radiation Physics
Institute of Clinical Sciences, Department of Surgery
Institute of Clinical Sciences, Department of Plastic Surgery
Pages 498-504
Language en
Keywords 3-Iodobenzylguanidine, therapeutic use, Adrenal Gland Neoplasms, radiotherapy, Humans, Iodine Radioisotopes, therapeutic use, Pheochromocytoma, radiotherapy
Subject categories Cancer and Oncology, Surgery


Malignant pheochromocytomas/paragangliomas (PCs/PGs) often have distant metastases to the skeleton, liver, and lungs. Radionuclide therapy is valuable for treatment of disseminated tumor disease and could be used as adjuvant therapy after surgery. Patients with local and/or distant metastases of PC/PG should be investigated preoperatively by scintigraphy using both 123I-MIBG and 111In-DTPA-D-Phe1-octreotide, to evaluate the possibilities for radionuclide therapy (i.e., a dosimetric estimation of radiation dose to the tumor tissue versus critical normal tissues). Individual patient dose-planning should be performed. For patients in whom positive therapeutic effects are anticipated radionuclide therapy can be applied. Therapy with both 131I-MIBG and 177Lu-octreotate might be favorable in individual patients with lesions visualized by both metaiodobenzylguanidine (MIBG) and octreotide scintigraphy with enhanced therapeutic effects and reduced side effects.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?